Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
November 10, 2008
- Eisai: Aricept, MGI Pharma's Products Push Up Sales 9.9%
November 10, 2008
- JSMI Adds 20 APIs as Candidates for Switch OTC Drugs
November 10, 2008
- MTPC: Sales Down 0.7% Despite Strong Growth of Remicade, Mearubik
November 10, 2008
- Taisho: Strong Self-med. Business Makes Up for Slump of Ethical Drugs Business
November 10, 2008
- DSP: New Products Make Up for Decreases in Sales of Amlodin
November 10, 2008
- SSP: Sales Remain Soft but Profits Jump
November 10, 2008
- Kyowa Hakko Kirin: Addition of Kirin Pharma Boosts Sales, Profits
November 10, 2008
- Nihon Chouzai, Matsumotokiyoshi to Ally to Open More Drugstores with Dispensing Services
November 10, 2008
- JT: Milestones Help Improve Pharmaceutical Business
November 10, 2008
- Council Recommends Early Approval of Intracranial Stent and Artificial Jaw Joint
November 10, 2008
- Torii: Business Hit by Generics of Futhan
November 10, 2008
- Eiken Chemical: Sales Up 2.9% but Full-year Profits Forecasts Revised Downward
November 10, 2008
- BUSINESS NEWS IN BRIEF
November 10, 2008
- MEDICAL DEVICE NEWS IN BRIEF
November 10, 2008
- Nippon Chemiphar: Sharp Drop in Profits Despite 5.8% Increase in Sales
November 10, 2008
- Colorectal Cancer Management GL to Be Revised in July 2009
November 10, 2008
- PMDA to Conduct More On-site Inspections Overseas for Generics
November 10, 2008
- GL in Preparation for Safer HRT
November 10, 2008
- COMMENTARY／Will World's Top Generic Maker Be Able to Succeed in Japan?
November 10, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…